XML 44 R33.htm IDEA: XBRL DOCUMENT v3.25.3

Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Net Sales and Operating Earnings by Segment

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

						Net Sales to External Customers												Cost of Products Sold												Research and Development												Selling, General and Administrative												Operating Earnings
						Three Months Ended September 30,												Three Months Ended September 30,												Three Months Ended September 30,												Three Months Ended September 30,												Three Months Ended September 30,
(in millions)						2025						2024						2025						2024						2025						2024						2025						2024						2025						2024
Established Pharmaceuticals						$	1,511					$	1,406					$	(714)					$	(644)					$	(42)					$	(46)					$	(364)					$	(336)					$	391					$	380
Nutritionals						2,153						2,066						(1,223)						(1,151)						(55)						(53)						(515)						(550)						360						312
Diagnostics						2,253						2,412						(1,290)						(1,280)						(150)						(165)						(413)						(409)						400						558
Medical Devices						5,448						4,747						(1,767)						(1,605)						(462)						(408)						(1,390)						(1,221)						1,829						1,513
Total						$	11,365					$	10,631					$	(4,994)					$	(4,680)					$	(709)					$	(672)					$	(2,682)					$	(2,516)					$	2,980					$	2,763
Other						4						4
Net sales						$	11,369					$	10,635
Corporate functions and plan benefit costs																																																						(84)						(140)
Net interest expense																																																						(44)						(51)
Share-based compensation (a)																																																						(120)						(117)
Amortization of Intangible assets																																																						(420)						(470)
Other, net (b)																																																						(132)						(45)
Earnings before Taxes																																																						$	2,180					$	1,940

						Net Sales to External Customers												Cost of Products Sold												Research and Development												Selling, General and Administrative												Operating Earnings
						Nine Months Ended September 30,												Nine Months Ended September 30,												Nine Months Ended September 30,												Nine Months Ended September 30,												Nine Months Ended September 30,
(in millions)						2025						2024						2025						2024						2025						2024						2025						2024						2025						2024
Established Pharmaceuticals						$	4,154					$	3,926					$	(1,914)					$	(1,819)					$	(127)					$	(131)					$	(1,078)					$	(1,014)					$	1,035					$	962
Nutritionals						6,511						6,284						(3,502)						(3,387)						(161)						(158)						(1,676)						(1,677)						1,172						1,062
Diagnostics						6,480						6,821						(3,666)						(3,671)						(455)						(482)						(1,228)						(1,206)						1,131						1,462
Medical Devices						15,712						13,934						(5,123)						(4,779)						(1,293)						(1,155)						(4,062)						(3,620)						5,234						4,380
Total						$	32,857					$	30,965					$	(14,205)					$	(13,656)					$	(2,036)					$	(1,926)					$	(8,044)					$	(7,517)					$	8,572					$	7,866
Other						12						11
Net sales						$	32,869					$	30,976
Corporate functions and plan benefit costs																																																						(177)						(286)
Net interest expense																																																						(143)						(170)
Share-based compensation (a)																																																						(551)						(562)
Amortization of Intangible assets																																																						(1,260)						(1,413)
Other, net (b)																																																						(333)						(452)
Earnings before Taxes																																																						$	6,108					$	4,983

______________________________________

(a)			Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)			Other, net for the three and nine months ended September 30, 2025 and 2024, includes charges related to restructurings. For the nine months ended September 30, 2025, Other, net includes a fair value adjustment to a contingent consideration. Other, net for the three and nine months ended September 30, 2024, includes charges related to impairment of IPR&D and costs related to business integration. Other, net for the nine months ended September 30, 2024, includes a loss on the divestiture of a non-core business.

Schedule of Depreciation, Additions to Property and Equipment, and Total Assets by Segment

						Depreciation												Additions to Property and Equipment
						Three Months Ended September 30,												Three Months Ended September 30,
(in millions)						2025						2024						2025						2024
Established Pharmaceuticals						$	28					$	23					$	38					$	52
Nutritionals						47						38						71						106
Diagnostics						136						129						168						183
Medical Devices						97						87						140						151
Total Reportable Segments						308						277						417						492
Other						63						54						70						77
Total						$	371					$	331					$	487					$	569

						Depreciation												Additions to Property and Equipment
						Nine Months Ended September 30,												Nine Months Ended September 30,
(in millions)						2025						2024						2025						2024
Established Pharmaceuticals						$	76					$	71					$	110					$	118
Nutritionals						133						116						231						282
Diagnostics						397						387						469						475
Medical Devices						279						261						441						444
Total Reportable Segments						885						835						1,251						1,319
Other						179						163						192						194
Total						$	1,064					$	998					$	1,443					$	1,513

Schedule of Reconciliation of Segment Assets to Total Assets

						Total Assets
(in millions)						As of September 30, 2025						As of December 31, 2024
Established Pharmaceuticals						$	3,730					$	3,087
Nutritionals						4,891						4,404
Diagnostics						8,201						7,678
Medical Devices						10,576						9,472
Total Reportable Segment Assets						$	27,398					$	24,641
Cash and investments						8,684						8,853
Goodwill and intangible assets						29,569						29,755
All other (c)						18,530						18,165
Total Assets						$	84,181					$	81,414

(c) As of September 30, 2025, and December 31, 2024, all other includes the long-term assets associated with the defined benefit plans and certain deferred tax assets.

X

- Definition

Tabular disclosure of all significant reconciling items in the reconciliation of total depreciation and additions to property, plant and equipment from reportable segments to the entity's consolidated amounts and segment assets

+ References

No definition available.

+ Details

Name:	abt_ReconciliationOfDepreciationAdditionsToPropertyPlantAndEquipmentFromSegmentToConsolidatedAndAssetsBySegmentTableTextBlock
Namespace Prefix:	abt_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration